Our polymeric nano-delivery system is transforming siRNA cancer gene therapy with:
Targets a key oncogenic factor in 17 cancer types.
Compatible with intravenous, intranasal, and direct tumor injection.
Maximizes cytotoxicity against cancer cells while preserving healthy tissues.
RNA Interference (RNAi) is a revolutionary gene-silencing technology that blocks disease-related protein synthesis. Our NORA siRNA therapy
Pharmaceutical R&D, Cancer Therapy & Brain-Targeted Delivery Solutions
We develop targated hydrogel nanoparticle-based therapeutics for oncology, inflammatory diseases, and neurodegeneration. Our work focuses on cancer management and therapy solutions, optimizing drug bioavailability, and improving treatment specificity.Additionally, we are pioneering brain-targeted delivery systems for brain cancers and Alzheimer’s disease. Our nanocarriers are engineered to cross the blood-brain barrier, ensuring targeted treatment with enhanced efficacy.
We design next-generation siRNA, RNAi, and precision therapeutics to optimize targeted cancer treatment strategies.
Conducting in vitro and in vivo studies to assess drug pharmacokinetics, efficacy, and biocompatibility.
Working with biotechnology firms, research institutions, and pharmaceutical companies to advance nanomedicine innovations.
Providing educational resources, therapy support, and personalized interventions for patients receiving advanced treatments.
Nanora Pharma is at the forefront of pharmaceutical innovation, dedicated to developing advanced treatments that improve lives worldwide. Our passion for science and commitment to health drive us to deliver groundbreaking solutions for today’s medical challenges.
